Chronos Archive seal

Review checklist: Howard Hughes (HR-ML006)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the DSM-5-TR OCD diagnosis with the insight specifier and the differential, sertraline titration to 200 mg with buprenorphine, the choice of sertraline over fluvoxamine, the augmentation plan held in reserve, the opioid use disorder count that excludes tolerance and withdrawal, buprenorphine induction from codeine and its use for pain, naloxone, the audiogram and hearing aids, and the plan for staff accommodation with his consent.
provenance reviewnot_startedSources: the Handbook of Texas, the Encyclopedia of World Biography and St. James Encyclopedia of Popular Culture (Encyclopedia.com), EBSCO Research Starters, a PBS History Detectives transcript, TIME (April and December 1976), BBC On This Day, OCD-UK (quoting Raymond Fowler's psychological study), a 1986 Canadian Journal of Psychiatry abstract, an MGH OCD program commentary and History.com. The New York Times obituary, the Smithsonian pages, the APA Monitor article and the biographies were not read. The OCD label is graded R.
safe messaging reviewnot_startedPsychiatric and substance claims are marked sensitive and recorded plainly without sensational detail; the roster's tissue-box and syphilis leads are not used; person-first language; codeine dependence after the crash is presented without blame. No relative or living person is named. The safety assessment gives the 988 Suicide & Crisis Lifeline and addresses means safety.

Judgment calls (dossier editorial resolutions)

  1. Sources. The New York Times obituary could not be fetched (the site refuses automated access), the Smithsonian National Air and Space Museum and Smithsonian magazine pages refused access, the APA Monitor article on Raymond Fowler's psychological study was blocked (it is used through OCD-UK's quotation), the UNLV Special Collections finding aids and Texas Monthly refused access, and the biographies by Donald Barlett and James Steele and by Richard Hack were not read. No claim relies on them. Quotations from a hearing-health blog and an audiology journal reprint were read but not used, because they contain errors (one gives the wrong date of death).
  2. Recent-death rule. He died in 1976, so the rule (deaths after 1990) does not apply. Psychiatric and substance claims are still marked sensitive (CLM-0003, CLM-0004, CLM-0006 to CLM-0009, CLM-0011, CLM-0012, CLM-0014), and a sick visit is included.
  3. Birth and death. Born December 24, 1905, in Houston (Handbook of Texas, Encyclopedia of World Biography, St. James Encyclopedia). Search results said that some accounts give Humble, Texas, as the birthplace and that a church baptismal register gives a different birth date; no fetched source confirmed either, so they are recorded here only, and the synthetic date of birth keeps December 24. Died April 5, 1976, aboard a plane from Acapulco to Houston (Handbook of Texas, Encyclopedia of World Biography, BBC, TIME). The St. James entry's August 16, 1976 is an error and is not used.
  4. Name. The display name is Howard Hughes, the name he used; it splits simply into given name Howard and family name Hughes, so identity.name_parts is not used and the C-CDA and FHIR names are Howard Hughes. The alias is his full name, “Howard Robard Hughes Jr.,” which appears in no other record. “Hughes” alone is not an alias, because it appears in other records as other people's names. The notes call him Mr. Hughes.
  5. Index age and dates. The index visit on May 4, 2026 maps to May 4, 1947, when he was 41: ten months after the XF-11 crash (July 7, 1946), long enough for pain and codeine use to have become long-term, and within the years when the sources describe his pain, his codeine dependence and his fear of germs. The synthetic date of birth is December 24, 1984 (shift 79). The visits on May 11, June 8, June 22, July 13, September 14 and October 5, 2026 map to the same days of 1947. He lived and worked in the Los Angeles area then (his aircraft company and the flying boat, which flew late in 1947); the sources read do not give his whereabouts day by day. No visit is placed in August 1947, when by common accounts he testified before a Senate committee in Washington; the month is not given in the fetched sources. Later choices considered: an index in 1958 would fall in the year of his documented breakdown, whose month is not documented.
  6. What is documented and what is interpretation. Documented (D): a lasting fear for his health after a boyhood paralysis (CLM-0003), a nervous breakdown in 1944 (CLM-0004), the crash and his injuries (CLM-0005), pain and codeine dependence after the crash (CLM-0006), a fear of germs that grew through his life (CLM-0007), a breakdown in 1958 (CLM-0009), deafness (CLM-0010), seclusion in hotels (CLM-0011), the procedures, poor eating and injected drugs of his last years (CLM-0012), his death (CLM-0013) and the autopsy findings (CLM-0014). The label obsessive-compulsive disorder is a retrospective interpretation (CLM-0008, R, probable). The sources do not date when his contamination fears began; the modern episode places them about a year before the index visit and worsening after the crash, which is synthetic. That the codeine was injected is not stated in the sources read (they say he injected drugs with a syringe, and that codeine was in his blood at death), so no claim says he injected codeine.
  7. Roster leads not used. The roster's syphilis lead was not found in any fetched source and is not used. The tissue boxes on his feet, and the claim that his case is “the most detailed OCD case in American history,” are sensational or unsupported and are not used. The roster's weight of 90 pounds at death is recorded as the TIME autopsy report gives it (“90-odd lbs.”).
  8. Relatives and others. No relative is named or given a role. His parents appear only as the context of his birth (CLM-0001). Raymond Fowler, James Phelan and the authors of the journal report are named only as authors of sources. His modern staff, assistant, cook, psychologist, physical therapist, dietitian and audiologist are synthetic and unnamed. No living person is named, and no other public figure is named in the modern episode.
  9. Synthetic clinical picture. Everything in the modern episode is synthetic: the contamination fears and their content, the Y-BOCS scores, the DSM-5-TR counts, every survey score (PHQ-9, GAD-7, DAST-10, AUDIT-C, PEG, PCL-5), all laboratory values, the audiogram, the urine drug tests and prescription monitoring results (narrative), the medicines, the staff plan and the outcomes. Height (191 cm) and weights are synthetic.
  10. Y-BOCS. The brief asked for the Y-BOCS as a coded survey. LOINC has no code for the Y-BOCS total score (searched on the terminology server and the web), and the C-CDA generator codes every observation as LOINC, so a SNOMED CT code (840418002, an assessment-scale concept) would be mislabeled. The Y-BOCS is therefore recorded in the mental status, problem and visit text and in each monitoring table, not as a coded observation.
  11. Presenting problems. Intrusive contamination fears with washing and avoidance (R46.81, obsessive-compulsive behavior) are the presenting problem, resolved at the consultation into obsessive-compulsive disorder (F42.2, mixed obsessional thoughts and acts; DSM-5-TR insight specifier “with good or fair insight”). Difficulty hearing (H91.93) resolves into bilateral sensorineural hearing loss (H90.3) at the five-week audiogram.
  12. Clinical judgment calls. (1) Opioid use disorder, moderate, is diagnosed at intake by counting four DSM-5-TR criteria and excluding tolerance and withdrawal, which do not count for a supervised prescription. (2) Buprenorphine with naloxone is chosen over a codeine taper, as the CDC 2022 guideline advises offering medication for opioid use disorder; it is split twice daily to help pain. (3) Sertraline rather than fluvoxamine, because fluvoxamine inhibits the enzymes that clear buprenorphine; titrated to 200 mg, the upper end of the OCD range. (4) Augmentation is held in reserve and not needed, because the Y-BOCS falls by half. (5) A PCL-5 screen is used to look for post-traumatic stress after the crash; it is below threshold. (6) Staff take part only with his written consent and are never asked to report on him. (7) Kidney function and albumin are followed because of his documented later illness, but no kidney disease is assigned in the modern frame.
  13. Preventive visit. A periodic adult preventive visit at 41 (CPT 99396 and 99497 in plain text). Judgment calls: HIV, hepatitis B and C tests at intake (narrative, negative; not immune to hepatitis B); lipids at the preventive visit (LDL 112 mg/dL, low 10-year risk, no statin); diabetes and colorectal screening not indicated (normal weight; under 45); influenza, Tdap and the first HepB-CpG dose, with the COVID-19 vaccine at his request at the twenty-two-week visit and the second hepatitis B dose the week after; advance care planning with an unnamed agent. The waiting-room chairs and shared pen serve as exposure exercises.
  14. Sick visit. Acute viral bronchitis seven weeks into buprenorphine and two weeks after the increase to sertraline 100 mg. It was chosen because it is common, insinuates no undocumented diagnosis, and tests the plan: no codeine cough syrup (opioid use disorder; buprenorphine blocks much of its effect), no dextromethorphan with sertraline, no antibiotic or chest X-ray by ACP and CDC criteria despite his old lung injury, and contamination fears about the illness met with facts given once, with reassurance-seeking treated as a ritual. It is not a historical claim; a news magazine's comment that the crash left him susceptible to bronchial infection (CLM-0007) is history only.
  15. Focused visits. The four chronic-care follow-ups (one week with the consultation, five weeks, ten weeks and twenty-two weeks) are documented as focused visits on the APA 2007 OCD guideline and its 2013 watch, NICE CG31, the CDC 2022 opioid guideline, the ASAM 2020 opioid use disorder guideline, NICE NG98, the CMID depression monograph (PHQ-9 and the two-week check after an SSRI change) and the VA/DoD suicide-risk guideline. Two deviations are recorded instead of invented results: (1) the two-week tolerability check after sertraline started was not done; he had no side effects at four weeks, and the corrective action was a nurse telephone call two weeks after each later dose change, which took place; (2) the five-week urine drug test was not collected because he could not use the clinic bathroom; the monitoring report showed only clinic prescriptions, and the test was collected at ten weeks as a planned exposure, positive for buprenorphine only. Synthetic findings introduced: the Y-BOCS course 28, 24, 19, 17 and 14; the audiogram; mild night sweats on sertraline; and his staff's step-by-step withdrawal from rituals.
  16. Consultation. The psychiatry referral and the consultation by Leonor Bachmann-Adeyemi, MD (a fictional consultant), on the day of the one-week visit, are S. The consultant answers the six referral questions in line with what the record shows afterwards: obsessive-compulsive disorder with good or fair insight, not obsessive-compulsive personality disorder, illness anxiety, post-traumatic stress disorder or psychosis; sertraline from 50 mg toward 200 mg, preferred to fluvoxamine because of buprenorphine; weekly then twice-weekly exposure and response prevention; his assistant in two sessions with his consent and staff stepping back in planned stages; augmentation or clomipramine only after a poor response (not needed); and agreement with the safety plan.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-06-08
Progress note 03 (C-CDA)
SSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughtsEvery visit, and two weeks after each start or dose changeThe two-week tolerability check after sertraline started was not done. No harm: he had no side effects, activation or suicidal thoughts at four weeks. Corrective action: a nurse telephone call two weeks after each dose change, booked today
2026-06-08
Progress note 03 (C-CDA)
Urine drug test with fentanyl and buprenorphine, with consentAt start, then about monthly in the first monthsNot collected: he could not use the clinic bathroom because of contamination fears. No sign of harm: no other prescriptions on the monitoring report, and he reports no other use. Corrective action: the test is the next step on his exposure hierarchy, with his therapist, at the ten-week visit

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-05-11
Progress note 02 (C-CDA)
ReferralExposure and response prevention: sessions attended and home practiceOrderedWeekly sessions with the clinic psychologist booked from next week
2026-05-11
Progress note 02 (C-CDA)
Self-managementAccommodation by staff, reduced step by step with his consentOrderedWritten consent signed for his assistant to join two sessions; staff will not be asked to report on him
2026-05-11
Progress note 02 (C-CDA)
ReferralPhysical therapy and graded activityOrderedPhysical therapy booked
2026-05-11
Progress note 02 (C-CDA)
ImagingHearing: audiometry, hearing aids and useOrderedAudiogram booked for the morning of the five-week visit

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0008Psychiatrists and OCD clinicians have described his behavior, retrospectively, as a severe contamination-type obsessive-compulsive disorder; one journal report calls his case an unusual end state of obsessive-compulsive neurosis in which a germ phobia coexists with neglect of personal hygiene.probable

Sensitive claims

ClaimGradeStatement
CLM-0003DAfter an unexplained paralysis in 1919, as a boy, he developed what a state historical handbook calls a lifetime phobic regard for his health; a psychologist who studied his life after his death concluded that his fear for his health began in childhood.
CLM-0004DHe suffered a nervous breakdown in 1944.
CLM-0006DDrugs for pain were first given to him after the 1946 crash; the crash left him with lingering pain and an addiction to codeine, the beginning of a lifelong dependence on painkillers.
CLM-0007DHis fear of germs grew throughout his life, with efforts to protect himself from contamination from outside; a news magazine linked his celebrated fear of germs in part to the 1946 crash, which injured his lungs and left him susceptible to bronchial infection.
CLM-0008RPsychiatrists and OCD clinicians have described his behavior, retrospectively, as a severe contamination-type obsessive-compulsive disorder; one journal report calls his case an unusual end state of obsessive-compulsive neurosis in which a germ phobia coexists with neglect of personal hygiene.
CLM-0009DBusiness pressures drove him to an emotional breakdown in 1958, and he was not seen in public after 1958.
CLM-0011DFrom the 1950s he lived in growing seclusion, conducting business through memos; he lived on the top floor of the Desert Inn in Las Vegas from 1966 to 1970, then moved between hotels in the Bahamas, Nicaragua, Canada, England and Mexico, arriving unannounced and taking extreme precautions for privacy.
CLM-0012DIn his later years his staff followed elaborate procedures to protect him from germs, such as wrapping objects in tissue before handing them to him; he lived in darkened rooms, ate little, injected drugs with a syringe, and became emaciated from too little food and too many drugs.
CLM-0014DThe autopsy in Houston attributed his death to kidney failure; he weighed only about 90 pounds, his kidneys had shrunk to less than half their normal size, and codeine and diazepam (Valium) were found in his blood.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-06-08Left ear threshold at 1000 Hz30 dB (high)High
2026-06-08Right ear threshold at 2000 Hz35 dB (high)High
2026-06-08Left ear threshold at 2000 Hz40 dB (high)High
2026-06-08Right ear threshold at 4000 Hz60 dB (high)High
2026-06-08Left ear threshold at 4000 Hz65 dB (high)High